Pharmaceutical Supply – Flumazenil Injection (FDA-Approved)

The contract awards the supply of one package of Flumazenil Injection, an FDA-approved sterile medication used to reverse the effects of benzodiazepines, ensuring full compliance with USP standards and all applicable federal regulatory requirements. The medication is intended for medical use in emergency settings and must meet stringent quality and safety protocols as mandated by U.S. pharmaceutical regulations. This subcontract is issued under the Department of Defense by the Defense Logistics Agency, classified under NAICS code 325412 for pharmaceutical preparation manufacturing, and is part of the broader defense healthcare supply chain aimed at maintaining clinical readiness. The procurement was posted on July 16, 2026, and is linked to contract SPE2DX25D8022 with delivery order SPE2D926F7402, though no specific place of performance or point of contact details are provided. The agreement does not qualify for any set-aside programs and is structured as a subcontract, indicating it may be part of a larger supply chain managed by a prime contractor. All deliverables must adhere to federal guidelines for sterile injectables, with quality control measures enforced throughout manufacturing and distribution to ensure the product’s integrity and effectiveness upon administration.